Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation Study (REWRAPS)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 500 participants.

Also called NCT02024230

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 500 participants (enrolled count) (from the registry)
Sponsor
Fujita Health University (from the registry)
Registry
  • NCT NCT02024230
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02024230. Non-randomized; no masking; primary purpose treatment. Start 2014-01 (actual); primary completion 2018-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation Study (REWRAPS)
Acronym
REWRAPS
Condition
Stroke
Condition
Fetal Blood Loss
Condition
Major Bleeding
Condition
All Cause Mortality
Intervention (Drug)
Rivaroxaban or Warfarin
Lead sponsor
Fujita Health University (class: other)

Record details

Record id
cardio:ct-nct02024230
Content hash
5720972bc5af9d0ee7eea4411d2b26e1e6b81138a8c083f6f4c17f81e50f0cff